Prenatal and Newborn Genetic Testing Market Report to 2027

[Research Report] The prenatal and newborn genetic testing market was valued at US$ 4,034.4 million in 2018 and it is projected to reach US$ 11,204.7 million in 2027; it is expected to grow at a CAGR of 12.2% from 2019 to 2027.

Prenatal genetic testing is performed during the pregnancy for the diagnosis of the diseases or detection of specific genetic abnormalities before 8 to 10 weeks of gestation and also helps to determine the sex of the fetus. Most of the prenatal genetic tests use a blood sample from the mother for conduction of various screens. Diagnostic methods are more effective, accurate, and a preferred option for the detection of chromosome abnormalities as compared to the screening methods. The growth of the global prenatal and newborn genetic testing market is attributed to the increase in the prevalence of genetic diseases among infants, supportive government for promoting the use of prenatal and newborn testing and increasing birth rate. However, risk associated with prenatal genetic tests is the major factor hindering the market growth.

The global prenatal and newborn genetic testing market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Lucrative Regions for Global Prenatal and Newborn Genetic Testing Market

Get more information on this report : Request Free Sample PDF

Market Insights

High Prevalence of Genetic Diseases in Infants to Drive Global Prenatal and Newborn Genetic Testing Market Growth

Several types of genetic diseases affect the fetuses in the womb. The way in which these genetic diseases are inherited helps to determine the risk that they pose on pregnancy as well as the risk of its recurrence. The risk of having genetic diseases in babies is high in cases where the parents have another child with a genetic disease, family history of a genetic disorder, or if either of a parent has a chromosomal abnormality. There is a significant prevalence of genetic diseases among infants. Moreover, these diseases are also responsible for infant mortality across the globe. For instance, according to the World Health Organization 2016, an estimated 7.9 million infants across world are born with genetic defects. Moreover, according to the Centers for Disease Control and Prevention (CDC), birth defects affects every 1 in 33 babies born in the US. On the other hand, chromosomal abnormalities such as Down syndrome affects 1 in 691 babies born in the US, as per the CDC’s data in 2017. 

On the other hand, a survey conducted by John Hopkins University in 2015 states that approximately 20-30% of infant deaths are a result of genetic disorders. Some of the major genetically determined metabolic diseases include sickle cell anemia, phenylketonuria, thalassemia, and others. Down syndrome is the most common chromosomal disorder that affects around 6000 babies in the US, according to the CDC’s statistics. Moreover, according to a report published by Stanford’s Children Health in 2018, sickle cell anemia occurs in almost 1 out 365 black African-American births. Thus, the high prevalence of genetic diseases among infants account for the increasing demands for prenatal and newborn genetic tests, thereby contributing to the growth of the market.

Product -Based Insights

In terms of product, the global prenatal and newborn genetic testing market is segmented into screening and diagnostics. In 2018, the screening segment held largest share of the market. Also, the same segment is estimated to register the highest CAGR during the forecast period.

Global Prenatal and Newborn Genetic Testing Market, by Product– 2018 and 2027

Get more information on this report : Request Free Sample PDF

Disease Indication-Based Insights

In terms of disease indication, the global prenatal and newborn genetic testing market is segmented into cystic fibrosis, sickle cell anemia, downs syndrome, phenylketonuria and other diseases. In 2018, the down syndrome segment held largest share of the market. However, the cystic fibrosis segment is expected to register the highest CAGR during the forecast period.

End User-Based Insights

In terms of end user, the global prenatal and newborn genetic testing market is segmented into hospitals & clinics, diagnostic centers and other end user. The hospitals and clinics segment held the largest share of the market in 2018. However, the diagnostics segment is estimated to grow at the fastest rate during the forecast period.

Strategic Insights

The global prenatal and newborn genetic testing market players are adopting the product launches, partnerships, and acquisitions to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Global Prenatal and Newborn Genetic Testing Market – by Product

• Diagnostic  

• Spectrophotometer
• Polymerase Chain Reaction
• Fluorescence in-situ Hybridization
• Array-Comparative Genomic Hybridization

• Screening

• Maternal Serum Screening
• Chronic Villus Sampling
• Amniocentesis
• Non-invasive Prenatal Testing

Global Prenatal and Newborn Genetic Testing Market – by Disease Indication

• Cystic Fibrosis
• Sickle Cell Anemia
• Down Syndrome
• Phenylketonuria
• Other Diseases

Global Prenatal and Newborn Genetic Testing Market – by End- User

• Hospitals & Clinics
• Diagnostic Centres
• Other End Users

Global Prenatal and Newborn Genetic Testing Market – by Geography

• North America

  • US
  • Canada
  • Mexico

• Europe

  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe

• Asia Pacific (APAC)

  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC

• Middle East & Africa (MEA)

  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

• South America and Central America (SCAM)

  • Brazil
  • Argentina
  • Rest of SCAM

Company Profiles

• Abbott
• Quest Diagnostics Incorporated
• Ravgen
• Bio-Rad Laboratories, Inc.,
• Illumina, Inc.
• F. Hoffmann La-Roche Ltd.
• Qiagen
• Berry Gene
• PerkinElmer, Inc.
• Natera, Inc.
• Laboratory Corporation of America Holdings (Sequenom)